Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | MYT1 | Q01538 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13563255 | 0.85 | DPP4 (0.39) | DPP4DPP8DPP7NOTUMRIPK1 | |
| SCHEMBL9944473 | 0.83 | DPP4 (0.39) | DPP4DPP8DPP7NOTUMRIPK1 | |
| SCHEMBL22590473 | 0.79 | DPP4 (0.38) | DPP4DPP8DPP7NOTUMRIPK1 | |
| SCHEMBL22968395 | 0.78 | DPP4 (0.42) | DPP4DPP8DPP7NOTUMRIPK1 | |
| SCHEMBL23921850 | 0.75 | DPP4 (0.36) | DPP4DPP8DPP7NOTUM | |
| SCHEMBL13562737 | 0.71 | DPP4 (0.37) | DPP4DPP8DPP7NOTUMMYT1 | |
| SCHEMBL9945822 | 0.70 | P2RX7 (0.40) | DPP4DPP8DPP7 | |
| SCHEMBL17538410 | 0.70 | DPP4 (0.39) | DPP4DPP8DPP7NOTUMMYT1 | |
| SCHEMBL9945669 | 0.70 | DPP4 (0.48) | DPP4DPP8DPP7 | |
| SCHEMBL25037642 | 0.68 | DPP4 (0.38) | DPP4DPP8DPP7NOTUMMYT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 7/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.